By Scott Patterson, Consulting SME for Pharma Containment and Powder Handling
High-potency cytotoxic payloads are vital for anti-cancer Antibody-Drug Conjugates (ADCs), and currently most ADC production is outsourced to CDMOs. It's important for drug research and development parties to prioritize containment controls for regulatory compliance, mitigating the potential exposure risks and reducing cross-contamination risk. ADCs face a high failure rate in clinical trials due to design complexity, payload toxicity, and other factors.
Enhance your ADC manufacturing processes by leveraging the performances and inherent benefits of single-use isolators, including:
- High-Containment Performance
- Flexibility & Process Simplification
- Economic Benefits
- And Sustainability